Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DuoBody®-CD3-H101GxB7H4
GEN1047 · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. | BIOLOGICAL | GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial. |
GEN1047 is an investigational bispecific antibody being studied for the treatment of solid tumors, including breast cancer and breast neoplasms. It is also being evaluated in endometrial cancer, ovarian cancer, and squamous non-small cell lung cancer. It is not yet approved for any indication and remains in clinical development.
GEN1047 is a bispecific antibody that targets B7H4-positive tumor cells and induces T-cell mediated cytotoxicity against them. By engaging both T cells and B7H4-expressing tumor cells, it directs an immune attack on the cancer cells. This mechanism is being evaluated in solid tumor indications.
GEN1047 is being developed by Genmab A/S, a biotechnology company listed under the ticker GMAB. Genmab is the sponsor of the clinical program evaluating this bispecific antibody in solid tumors.
GEN1047 is in Phase 2 clinical development. The ongoing first-in-human trial is a Phase 1/Phase 2 study, and the drug has not yet been approved by the FDA or any regulatory agency. It remains an investigational therapy for solid tumors.
GEN1047 is being evaluated in a first-in-human trial, NCT05180474, titled GEN1047 for Solid Tumors - First in Human (FIH) Trial. This Phase 1/Phase 2 study has enrolled 179 participants and is currently active but not recruiting. It includes breast cancer, endometrial cancer, ovarian cancer, and squamous non-small cell lung cancer.
Yes, GEN1047 is also referred to by its full descriptive name: a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. Both names refer to the same investigational agent developed by Genmab A/S for solid tumors.